Interferon-Beta Prevents Cytokine-Induced Neutrophil Infiltration and Attenuates Blood

Abstract

Inflammation can contribute to brain injury, such as that resulting from ischemia or trauma. The authors have previously shown that the cytokine interferon-beta (IFN-β) affords protection against ischemic brain injury, which was associated with a diminished infiltration of neutrophils and a reduction in blood–brain barrier (BBB) disruption. The goal of the current study was to directly assess the effects of IFN-β on neutrophil infiltration, with the use of an in vivo assay of neutrophil infiltration with relevance to ischemic brain injury. Intrastriatal injection of recombinant rat cytokine–induced neutrophil chemoattractant-1, a member of the interleukin-8 family (1 μg in 1 μL), triggered massive infiltration of neutrophils and extensive BBB disruption 6 hours later, as measured using immunofluorescence microscopy and magnetic resonance imaging in the rat, respectively. Depleting the animals of neutrophils before interleukin-8 injection prevented BBB disruption. Treatment with IFN-β (5 × 10⁶ U/kg) almost completely prevented neutrophil infiltration and attenuated BBB damage. Gelatinase zymography showed matrix metalloproteinase-9 expression in the ipsilateral striatum after interleukin-8 injection. Both neutrophil depletion and IFN-β treatment downregulated matrix metalloproteinase-9. IFN-β has already been approved for human use as a treatment for the chronic inflammatory disorder multiple sclerosis. The potential value of IFN-β as a treatment that can attenuate acute brain inflammation is considered.

Keywords

Interleukin-8 Interferon-beta Inflammation Neutrophil infiltration Blood-brain barrier disruption Acute neurodegeneration

The inflammatory response to acute insults such as cerebral ischemia or trauma can contribute to brain injury (Barone and Feuerstein 1999; DeGraba 1998; Iadecola and Alexander 2001). Hallmarks of the acute phase of the inflammatory response are the opening of the blood–brain barrier (BBB) and the infiltration of neutrophils. Cytokines orchestrate the response and, as such, constitute powerful intermediates through which the response may be altered to achieve therapeutic benefit.

We have previously shown that the cytokine interferon-beta (IFN-β) significantly reduced infarct volume after transient ischemic stroke in the rat (Veldhuis et al., 2002). The reduction in lesion volume was associated with a diminished infiltration of neutrophils and an attenuated disruption of the BBB. Because ischemic injury induces a plethora of cytokines and a complex inflammatory response, it is difficult to determine whether IFN-β directly prevents neutrophil influx or whether this effect is secondary to some other mechanism. In multiple sclerosis, the effect of IFN-β on monocyte and T-cell infiltration has been attributed to downregulation of adhesion molecules (Calabresi et al., 2001; Defazio et al., 2000; Floris et al., 2002; Lou et al., 1999) and matrix metalloproteinase (MMP)-9 expression (Galboiz et al. 2001; Stuve et al. 1997; Trojano et al. 1999; Waubant et al., 2001). The goal of the current study was to directly assess the effects of IFN-β on neutrophil infiltration, with the use of an in vivo assay of neutrophil infiltration with relevance to ischemic brain injury while avoiding the complexity of ischemia-induced inflammation. To this end, the α-chemokine cytokine-induced neutrophil chemoattractant-1, a member of the interleukin-8 (IL-8) family, was injected directly into the rat striatum. IL-8 is considered to be the prototypic and most potent neutrophil-attracting chemokine, attracting neutrophils to a wide variety of organ systems (Baggiolini et al., 1995; Mukaida et al., 1998a). After cerebral ischemia, IL-8 upregulation by glia and endothelium (Ehrlich et al., 1998; Stanimirovic and Satoh, 2000; Stanimirovic et al., 2001) precedes neutrophil influx (Yamagami et al., 1999; Yamasaki et al. 1995), and treatment with antibodies against IL-8 prevents influx and reduces ischemic damage (Matsumoto et al. 1997a,b; Mukaida et al., 1998b). In addition, the neutrophil chemotactic activity induced by production or injection of the key proinflammatory cytokines tumor necrosis factor-α (TNF-α) or interleukin-1β (IL-1β) has been attributed to IL-8 (Anthony et al., 1998; Tada et al., 1993). So far, a limited number of studies have reported on the injection of proinflammatory cytokines in a setting of acute neurodegeneration. These studies have mainly focused on IL-1β or TNF-α (Bernardes-Silva et al., 2001; Blamire et al., 2000; Liu et al., 1994; Rosenberg et al., 1995; Watts et al., 1989; Yamasaki et al., 1992). The effects of injection of α-chemokines such as IL-8 have been studied only in the mouse (Andersson et al., 1992; Bell et al., 1996).

In this study, we applied magnetic resonance imaging (MRI) because of its potential to detect acute tissue changes such as those occurring after ischemia, structural tissue abnormalities, and functional properties such as hemodynamics and BBB integrity. Immunofluorescence microscopy and gelatinase zymography were performed to confirm neutrophil infiltration and to obtain mechanistic information on the effects of IL-8 injection and IFN-β treatment. To assess the contribution of neutrophils to the consequences of IL-8 injection, these assays were also carried out in a group of animals that was depleted of neutrophils before the experiment.

MATERIALS AND METHODS

Animal model

Male Fischer rats (F344/Ico, Iffa-Credo Broekman, Someren, The Netherlands) aged 3 weeks were used. Animals had free access to standard laboratory chow and water. Anesthesia was induced by injection of a mixture of 0.5-mL/kg fentanyl citrate (0.315 mg/mL, intraperitoneally) and fluanisone (10.0 mg/mL, intraperitoneally), and 0.5-mL/kg midazolam (5.0 mg/mL, intraperitoneally). Body temperature was maintained at 37°C by means of a feedback-controlled heating pad and an infrared heating lamp. A small burr hole was drilled in the cranium over the left hemisphere, 2.5 mm lateral and 0.5 mm anterior of bregma. A 1-μL syringe was lowered into the right striatum to a depth of 4.0 mm. Recombinant rat IL-8 (cytokineinduced neutrophil chemoattractant-1; R&D Systems, Minneapolis, MN, U.S.A.; 1.0 μL, 1-μg/μL in PBS with 50-μg/μL BSA; n = 13) or vehicle (1.0 μL PBS with 50-μg/μL BSA; n = 2) was injected at a rate of 0.125 μL/min using a microdrive. After injection, the needle was left in situ for 2 minutes to avoid leakage of injection fluid from the needle tract. Between the end of the injection procedure and the start of the MRI measurements, the animals were kept in a temperature-controlled environment (31°C). Before the MRI measurements, the animals were reanesthetized using 5% halothane in N₂O/O₂ (70/30, volume/volume). In the scanner, anesthesia was continued using 1% to 1.5% halothane, and body temperature was maintained using a feedback-controlled water-filled heating pad. The Utrecht University Animal Experiment Ethical Committee approved all animal experiment protocols.

Recombinant rat IFN-β

The cloning and expression of the chromosomal gene encoding rat IFN-β in Chinese hamster ovary cells have been described elsewhere (Ruuls et al., 1996). The glycoprotein was purified to homogeneity by dye-ligand affinity chromatography and analyzed for endotoxin contamination. The biologic activity of each batch was determined in an antiviral bioassay (Olsson et al., 1994) and compared with the bioactivity of a laboratory standard preparation. Purified recombinant rat IFN-β was found to exert a bioactivity of approximately 5 × 10⁷ U/mg of protein. IFN-β–treated animals received dosages on the basis of equal bioactivity per kilogram of body weight.

Magnetic resonance imaging

Magnetic resonance imaging experiments were performed using a 4.7-T horizontal bore spectrometer (Varian Instruments, Palo Alto, CA, U.S.A.) with a 220-mT/m gradient insert. Radio frequency-excitation and signal detection were accomplished by means of a Helmholtz volume coil (9-cm diameter) and an inductively coupled surface coil (2-cm diameter), respectively. A rapid spin-echo scout sequence was used for determination of the position of the animal in the magnet and subsequent slice planning (repetition time [TR] = 15 milliseconds, echo time [TE] = 600 milliseconds, matrix [M] = 64 × 64, field of view [FOV] = 40 × 35 mm², number of transients [NT] = 1, acquiring 21 consecutive 1.0-mm-thick sagittal slices).

Diffusion-weighted imaging. For diffusion-weighted MRI, a single-shot diffusion-trace MRI sequence was used (4 b values: 100–1,780 s/mm², TR = 2 seconds, TE = 100 milliseconds, NT = 2, 7 consecutive 1.7-mm-thick slices, FOV = 22 × 22 mm², M = 64 × 64, zero-filled to 256 × 256) (de Graaf et al., 2001).

T₂-weighted imaging. T₂W-MRI datasets were acquired using a multi-echo sequence (8 TEs: 17.5 milliseconds + 7 × 17.5 milliseconds, TR = 3 seconds, NT = 2, 12 consecutive 1.0-mm-thick slices, FOV = 22 × 22 mm², M = 128 × 64, zero-filled to 256 × 256).

Imaging BBB permeability. To assess BBB disruption, 150 μL of a standard gadolinium-based MRI contrast agent (Magnevist [Gd-DTPA], Schering, Berlin, Germany) was injected via a tail vein (Runge et al., 1994). Before injection, high-resolution T1-weighted datasets were acquired (TR = 0.65 seconds, TE = 0.0125 seconds, NT = 2, FOV = 22 × 22 mm², M = 128 × 128, zero-filled to 512 × 512). Fifteen minutes after injection, identical but contrast-enhanced datasets were acquired.

Perfusion imaging. During the passage of the above bolus of contrast agent, dynamic susceptibility contrast-enhanced MRI was performed, acquiring 120 images of a 1.5-mm-thick slice through the center of the lesion, 0.5 mm anterior to bregma, using a FLASH sequence with the following parameters: TR =11 milliseconds, TE = 7 milliseconds, NT = 1, flip angle = 15°, FOV = 22 × 22 mm², M = 64 × 64, zero-filled to 256 × 256.

Experimental protocol

Six hours after injection of IL-8, the animals were transferred to the MRI scanner for perfusion imaging and assessment of BBB disruption. IL-8 injected animals were divided into three groups: (1) animals that received IL-8 alone (n = 4), (2) animals that received recombinant rat IFN-β before IL-8 injection (n = 4), and (3) animals that received neutrophil-depletion treatment before IL-8 injection (n = 3). To look for structural effects of IL-8 injection on brain parenchyma, two additional animals received IL-8 injection with no prior treatment, and at 24 hours, contrast-enhanced T₁-weighted MRI and diffusion-weighted and T₂-weighted datasets were acquired. Neutrophil depletion was induced by injection of rabbit antirat, antineutrophil serum (Accurate Chemical & Scientific, Westbury, NY, U.S.A.; 3 mL/kg, intraperitoneally) at 24 hours and again at 5 hours before IL-8 (Blamire et al., 2000). Animals treated with recombinant rat IFN-β (5 × 10⁶ U/kg, intraperitoneally) received injections at 48, 24, and 0.5 hours before IL-8 injection. This treatment regimen was chosen based on maximal prevention of leukocyte infiltration reported in a rat model of multiple sclerosis (van der Meide et al., 1998). After the MRI experiments, the animals were killed and the brains were directly removed without perfusion or fixation and processed for immunohistology and gelatinase zymography.

Immunofluorescence microscopy

After the animals were killed, the brains were dissected, snap-frozen in the vapor phase of liquid nitrogen, and stored at −80°C. Cryostat sections (8 μm) were cut, and we analyzed the sections close to the center of the lesion (bregma + 0.5 mm), just avoiding the needle tract. Sections were melted onto gelatin-coated glass slides and dried in containers with silica gel. Slides were fixed with acetone (for 10 minutes) and incubated in PBS with 10% fetal calf serum to prevent aspecific binding. Thereafter, immunohistochemistry was performed. Infiltrated leukocytes were detected with the monoclonal antibody OX1, directed against CD45 (Biotinylated mIgG1; obtained from Serotec, Oxfordshire, UK). Neutrophil infiltration was determined by monoclonal antibody HIS48, which recognizes an antigen on all neutrophils (van Goor et al., 1991) (Biotinylated mIgM; BD Biosciences). Activated microglial cells were detected with the monoclonal antibody OX42, which recognizes the iC3b receptor (biotinylated mIgG2a) obtained from Serotec (Oxfordshire, UK). Intercellular adhesion molecule-1 (ICAM-1) expression was determined by the monoclonal antibody 1A29 (mIgG1; a gift from Dr. T. Tamatani, Tokyo Metropolitan Institute of Medical Science, Japan). Cerebral blood vessels were detected by an antibody directed against von Willebrand factor (rabbit antihuman, Dako, Denmark). Slides were incubated with the antibodies at appropriate dilutions (2.5 μg/mL) for 1 hour at room temperature. To detect primary antibodies, the following conjugates were used: streptavidin Alexa-488, goat anti–mouse Alexa-488, and donkey anti–rabbit Alexa-594 (all obtained from Molecular Probes, Eugene, OR, U.S.A.). Omission of the primary antibodies served as negative control. The sections were examined with a microscope (Nikon Eclipse E800), and recordings were made with a digital NIKON DXM1200 camera.

Gelatinase zymography

Gelatinase extraction. For determination of gelatinase activity, 10 cryostat sections of 30 μm were acquired from the center of the lesion and homogenized in 500 μL lysis buffer. The lysis buffer was composed of 50-mmol/L Tris-HCl (pH 8.0), 150-mmol/L NaCl, 1-mmol/L EDTA, and 1% NP-40. After incubation for 1 hour at 4°C, the homogenate was centrifuged for 15 minutes at 15,000g at 4°C, and the supernatant was recovered. Gelatin-Sepharose purification was performed on the supernatant, adapted from (Zhang and Gottschall, 1997). Briefly, 500 (μ supernatant was incubated and rotated for 1 hour with 50 μL of gelatin-Sepharose 4B (Pharmacia Biotech, Uppsala, Sweden) with constant shaking. After incubation and centrifugation (800g, 5 minutes at 4°C), the supernatant was discarded, the gelatin-Sepharose pellet was resuspended in 500 μL working buffer (50-mmol/L Tris-HCl, 150-mmol/L NaCl, 5-mmol/L CaCl₂), and the solution was centrifuged again (800g, 5 minutes at 4°C). The pellet was incubated with 150 μL of elution buffer consisting of working buffer supplemented with 10% dimethylsulfoxide. Gelatinase activity in the eluent was measured by gelatin zymography.

Gelatin-substrate zymography. Matrix metalloproteinases 2 and 9 were analyzed by zymography, which is based on the ability of (pro-)MMPs to digest gelatin in polyacrylamide gels. Samples (20 μL) were added to nonreducing sample buffer (0.5-mol/L Tris-HCl, pH 6.8, 20-mg/mL sodium dodecyl sulphate, 8-mg/mL sucrose, and 0.2-mg/mL bromophenol-blue; 20 mL). Twenty-five microliters per lane of the mixture was loaded on polyacrylamide gels (9.5% acrylamide, 0.3% bisacrylamide, 0.2% gelatin, 0.1% sodium dodecyl sulphate in 0.375-mol/L Tris-HCl [pH 6.8]). Together with the samples, protein standards (kaleidoscope prestained standard, Bio-Rad, CA, U.S.A.) and a positive control containing pro–MMP-2 (supernatant from the human neuroblastoma cell line SK-N-SH incubated for 48 hours in serum-free medium) were run. After electrophoresis (20 mA/gel) in running buffer (25-mmol/L Tris, 0.19 M glycine and 3.5-mmol/L sodium dodecyl sulphate, dissolved in demineralized water), the gels were gently shaken for 3 × 10 min in renaturing buffer (2.5% Triton X-100 [volume/volume] in water) to remove the sodium dodecyl sulphate and restore enzyme activity during incubation. The gels were subsequently shaken for 3 × 5 minutes in developing buffer, pH 8.0 (50-mmol/L Tris-HCl, pH 7.5, 0.2-mol/L NaCl, 5-mmol/L CaCl₂, and 0.1-μmol/L ZnCl₂), and then incubated overnight at 37°C in 50 mL developing buffer. Finally, the gels were stained overnight in a staining solution (7.5% acetic acid, 5.0% ethanol, and 0.25% Coommassie Brilliant blue R-250) and destained for 4 hours in the same solution but without Coommassie Brilliant blue. Proteolytic activity was identified as a clear band against a blue background.

Data analysis

Blood–brain barrier disruption was determined from the increase in signal intensity (using ≥2 × SD compared with contralateral as the threshold) induced by the accumulation of Gadolinium-DTPA in the brain parenchyma (Blamire et al., 2000; Stone et al., 1995), using the Interactive Data Language software package (Research Systems, Boulder, CO, U.S.A.). Apparent diffusion coefficient and T₂ maps were generated from the diffusion-weighted and T₂-weighted magnetic resonance images by monoexponential fitting using the same software package. Gd-leakage images were constructed by subtracting the precontrast T₁-weighted dataset from the postcontrast dataset (Neumann-Haefelin et al., 2002). Voxels in the ipsilateral hemisphere were considered pathologic if their signal intensity had increased more than a factor 1.6 (corresponding to a ≥2 × SD difference) from the mean signal intensity of the brain parenchyma in the contralateral hemisphere. The volume of affected brain tissue was calculated by multiplying the number of pathologic voxels in a slice by the voxel volume. The total lesion volume was obtained by summation of the lesion volumes for all slices. DSC-enhanced MRI data were processed as described previously (Dijkhuizen et al., 1997). Briefly, the signal intensity drop induced by passage of the contrast agent was converted to an increase in the transverse relaxation rate, 1/T₂* (i.e., ΔR2*). Hemodynamic-parameter maps were calculated by pixel-by-pixel fitting of time plots of ΔR2* to a γ-variate function (Rosen et al. 1990). Relative cerebral blood volume (rCBV), mean transit time, and relative cerebral blood flow indices (rCBFi) were measured in the injected striatum and in the striatum on the contralateral side. Statistical analysis was carried out using SPSS 10.0 (SPSS Inc., Chicago, IL, U.S.A.). Reported P values correspond to two-tailed significance.

RESULTS

There were no differences between the treatment groups (control, IFN-β, and neutrophil depleted) in terms of increase in body weight between initial pharmacologic treatment and start of IL-8 injection, or in body weight at the start of IL-8 injection, as tested by one-way analysis of variance.

Effect of IL-8 injection on BBB integrity

The intravascular contrast agent Gd-DTPA cannot pass the intact BBB. To study the effect of IL-8 injection on BBB integrity, the leakage of Gd-DTPA into the brain parenchyma was determined from postcontrast T₁-weighted images. Injection of IL-8 resulted in extensive BBB breakdown as demonstrated by the leakage of contrast-agent into the brain parenchyma (Fig. 1). In vehicle-injected animals, the mechanical trauma caused by needle insertion resulted in only limited leakage, directly around the needle tract. The T₂-weighted and diffusion-weighted images acquired after 24 hours were normal, indicating that IL-8 injection caused no morphologic changes or edema formation (data not shown). The IL-8–induced opening of the BBB detected at 6 hours had normalized by 24 hours. By that time, only a small amount of Gd-DTPA leakage was detected, which was restricted to the region around the needle tract (data not shown).

FIG. 1.

Blood–brain barrier integrity assessed 6 hours after intrastriatal injection of IL-8. Shown are postcontrast T₁-weighted images of three animals, after subtraction of the precontrast datasets. Of each animal, five consecutive slices are shown in the rostrocaudal direction. The intravascular contrast agent Gd-DTPA cannot pass the intact BBB. At sites of BBB breakdown, the intraparenchymal presence of contrast agent is evidenced by increased signal intensity on T₁-weighted images. IL-8, interleukin-8; IFN- β, interferon-beta; PMN, polymorphonuclear neutrophil.

Effect of neutrophil depletion and IFN-β treatment on IL-8–induced BBB disruption

Depletion of neutrophils before the experiment prevented the IL-8–induced breakdown of the BBB (Fig. 1). In those animals, only minimal leakage, directly around the needle tract, was seen. Figure 2 shows the total volume of brain tissue showing a ≥2 × SD increase in signal intensity, including the region around the needle tract, of all animal groups. Treatment with IFN-β potently protected the brain from the IL-8–induced BBB breakdown, and brought down the degree of Gd-DTPA–induced signal enhancement, almost to the level achieved by neutrophil depletion (Figs. 1 and 2).

FIG. 2.

The total volume of brain tissue suffering from BBB disruption, including the region around the needle tract, as determined on the basis of a ≥2× SD increase in signal intensity on contrast-enhanced T₁-weighted difference images (postcontrast – precontrast). Bars represent mean ± SD. *P < 0.05 versus IL-8 alone. IL-8, interleukin-8; IFN-β, interferon-beta; PMN, polymorphonuclear neutrophil.

Effects of IL-8 injection and therapeutic intervention on hemodynamic parameters

Because changes in rCBV have been reported after IL-1β–induced BBB breakdown (Blamire et al., 2000), we determined whether there were changes in hemodynamic parameters after IL-8 injection. In animals that received IL-8 alone, rCBFi in the injected striatum was slightly lower than in the untreated striatum, whereas after polymorphonuclear neutrophil depletion rCBFi was increased (Fig. 3A). After IFN-β treatment, IL-8 injection did not result in changes in cerebral blood flow (Fig. 3A). The changes in rCBFi could not be attributed to changes in either mean transit time or rCBV alone, but instead derived from slight variations in both. Changes in mean transit time and rCBV were only small and did not significantly differ among the treatment groups (Figs. 3B and 3C).

FIG. 3.

Effect of IL-8 injection, IFN-β treatment, and neutrophil depletion on hemodynamic parameters. Relative cerebral blood volume (A), mean transit time (B) and relative cerebral blood flow indices (C) were measured in the lesioned striatum 6 hours after injection and compared with the striatum on the contralateral side. Bars represent mean ± SD. *P < 0.05 versus IL-8 alone. IL-8, interleukin-8; IFN-β, interferon-beta; PMN, polymorphonuclear neutrophil.

Effect of IFN-β on neutrophil infiltration and cellular activation

Immunofluorescent analysis was performed at the 6-hour time point to study the presence of neutrophils and analyze ICAM-1 expression and microglial activation in relation to the BBB breakdown detected by the MRI measurements. Intrastriatal injection of IL-8 resulted in massive infiltration of neutrophils, as identified by HIS48. Neutrophils were present in the perivascular space of cerebral blood vessels and in the brain parenchyma (Fig. 4). Furthermore, infiltrated cells expressed both CD45 (present on all leukocytes) and HIS48 epitope (present on neutrophils only), showing that all infiltrated cells were neutrophils (data not shown). In the animals that received IL-8 injection after neutrophil depletion, no cellular infiltrates were observed in the brain (Fig. 4). Similarly, treatment with IFN-β almost completely prevented the infiltration of neutrophils into the brain. Although in these animals careful scanning did reveal vessels with neutrophils, these were never found beyond the perivascular space (Fig. 4B).

FIG. 4.

Effect of IFN-β treatment and neutrophil-depletion on IL-8–induced neutrophil infiltration. (A) Shown are sections through the striatum for all three treatment groups. HIS48-positive neutrophils (in green) are present around von Willebrand factor–positive blood vessels (in red) in the striatum 6 hours after injection of IL-8 alone (IL-8), but not after neutrophil depletion (IL-8 + PMN-depletion) or IFN-β treatment (IL-8 + IFN-β). Scale bar = 500 μm. (B) High-magnification image of the vessels indicated in panel A with nuclei stained with Hoechst (in blue). Scale bar = 250 μm. IL-8, interleukin-8; IFN-β, interferon-beta; PMN, polymorphonuclear neutrophil.

To investigate whether the observed effect of IFN-β was associated with a reduced activation of brain endothelial or microglial cells, ICAM-1 and iC3b receptor expression were analyzed. IL-8 injection resulted in a clear upregulation of ICAM-1 on the cerebrovasculature in the ipsilateral striatum (Fig. 5). No upregulation of ICAM-1 was detected in the contralateral hemisphere (data not shown). Neither polymorphonuclear neutrophil depletion nor IFN-β treatment prevented the upregulation of ICAM-1 (Fig. 5). Staining for the iC3b receptor (CD11b) showed that the influx of neutrophils and the breakdown of the BBB after IL-8 injection were not associated with microglial activation, as judged by the unchanged expression of CD11b (data not shown).

FIG. 5.

Expression of ICAM-1 (in green) on von Willebrand factor-positive vascular endothelium (in red) in the striatum 6 hours after IL-8 injection. Neither IFN-β treatment nor neutrophil depletion prevented the IL-8–induced upregulation of ICAM-1 expression. Scale bar = 250 μm. IL-8, interleukin-8; IFN-β, interferon-beta; PMN, polymorphonuclear neutrophil.

MMP-9 activity after IFN-β treatment

During extravasation into the brain parenchyma leukocytes not only have to traverse the tight endothelial layer, but also the basement membrane of the blood vessel endothelium. To this end, infiltrating leukocytes produce MMPs. Because the effect of IFN-β on monocyte and T-cell infiltration in patients with multiple sclerosis has been attributed to downregulation of MMP-9 expression (Galboiz et al., 2001; Stuve et al., 1997; Trojano et al., 1999; Waubant et al., 2001), and because MMP-9 inhibition in stroke reduces infarct size (Romanic et al., 1998), we performed gelatinase zymography, after gelatin-Sepharose purification, to assess the levels of MMP-2 and MMP-9 after IL-8 injection. The assay showed two bands for MMP-9: one at 92 kd, which corresponds to pro–MMP-9, and another at 120 kd, which has been reported to correspond to MMP-9 complexed to lipocalin (Yan et al., 2001). Lipocalin is coexpressed in neutrophils with pro–MMP-9 and enhances its direct activation (Tschesche et al., 2001). In the lesion homogenates of all animals, a clear band of pro–MMP-2 (72 kd) and a weak band of active MMP-2 were observed. The effect of neutrophil depletion or IFN-β treatment was not mediated by a decrease in MMP-2 expression (Fig. 6). After IL-8 injection, a clear band of pro–MMP-9 was observed. Neutrophil depletion before IL-8 injection resulted in a decrease in pro–MMP-9 gelatinase activity (Fig. 6). A similar reduction in MMP-9 activity was seen in IL-8–injected rats treated with IFN-β. In both treatments groups, the band at 120 kd was absent (Fig. 6).

FIG. 6.

Gelatin zymogram showing upregulation of MMP-9 6 hours after intrastriatal IL-8 injection. IFN-β treatment or neutrophil depletion prevented the upregulation of the MMP-9 bands at 92 and 120 kd. Zymography was performed in duplicate. The lane labeled ‘+’ contains pro–MMP-2 from the SK-N-SH human neuroblastoma cell line. IL-8, interleukin-8; IFN-β, interferon-beta; PMN, polymorphonuclear neutrophil.

DISCUSSION

The mechanism of action of IFN-β as a treatment for the chronic inflammatory disease multiple sclerosis is incompletely understood. However, at least part of the benefit derived from its application is ascribed to reducing the influx of monocytes and T-cells into the brain (Floris et al., 2002; Yong et al., 1998). Recent experiments with IFN-β in an experimental stroke model suggested that the cytokine might also be of use as a treatment of brain insults that are accompanied by acute inflammation (Veldhuis et al., 2002). Therefore, in this study we have investigated the effect of IFN-β on IL-8–induced neutrophil infiltration into the rat brain, in a setting relevant to ischemic brain injury. The principal findings are that injection of IL-8 into the rat brain results in neutrophil-dependent BBB disruption, and that IFN-β prevents neutrophil infiltration and attenuates BBB disruption, presumably via an effect on MMP-9 release from neutrophils. These findings and their implications are discussed below.

Intracerebral IL-8 injection results in neutrophil influx and BBB disruption

After ischemia or trauma, proinflammatory cytokines are produced, which results in recruitment of neutrophils to the lesion area, breakdown of the BBB, and secondary tissue destruction. The present data show that 6 hours after injection of the chemokine IL-8 into the rat striatum, large numbers of neutrophils have entered the perivascular space and are infiltrating the brain parenchyma. This infiltration was accompanied by extensive damage to the BBB. Furthermore, BBB disruption did not occur after IL-8 injection in neutrophil-depleted animals. These findings of infiltration and neutrophil-dependent BBB disruption within hours after injection are in agreement with results from other studies inducing neutrophil recruitment by injecting the pleiotropic inflammatory mediator IL-1β (Bernardes-Silva et al., 2001; Blamire et al., 2000). However, IL-1β mediates many effects apart from inducing neutrophil influx (Rothwell and Luheshi, 2000; Wang and Shuaib, 2002). Even though IL-1β may be produced after injection of IL-8 (Matsukawa et al., 1995), the changes in rCBV and apparent diffusion coefficient seen after injections of IL-1β (Blamire et al., 2000) were not detected after injection of IL-8 in the current study. Blamire et al. (2000) were careful to point out that the IL-1 β–induced changes in apparent diffusion coefficient also occurred in neutrophil-depleted animals and may be related to direct cytotoxic effects of the injected cytokine. In addition, they have shown that the influx induced by IL-1β injection is mediated by IL-8 (Anthony et al., 1998). Intracerebral injection with TNF-α, another pleiotropic inflammatory cytokine relevant to ischemic injury (Barone et al., 1997; Wang and Shuaib, 2002), was also shown to induce both apparent diffusion coefficient and rCBV changes and induce BBB permeability (Sibson et al., 2001; Sibson et al., 2002). Although minor neutrophil infiltration occurred in those studies, injection of TNF-α into gliomas resulted in extensive neutrophil influx, which also contributed to IL-8 production (Tada et al., 1993). Thus, by using IL-8 in the current setup, we attempted to stimulate neutrophil recruitment with as few side effects as possible, enabling the direct assessment of the effect of IFN-β treatment on this influx. We did, however, detect a small decrease in rCBFi in the ipsilateral striatum after IL-8 injection. The cause for this decrease is unclear, but may be related to neutrophil recruitment, presumably reflecting their largescale attachment to the cerebral microvascular endothelium (Mori et al., 1992).

IFN-β prevents IL-8–induced neutrophil influx and attenuates BBB disruption

The current data show that IFN-β strongly limits the IL-8–induced influx of neutrophils into the brain. Therefore, IFN-β can directly influence neutrophil infiltration across the BBB. A tentative mechanism underlying the observed inhibition of neutrophil infiltration would be the prevention of ICAM-1 upregulation (Der et al., 1998). This mechanism has been suggested to play a role in the effect of IFN-β against multiple sclerosis (Trojano et al., 2000), although observations to the contrary have also been made (Corsini et al., 1997). We demonstrated that after IL-8 injection, ICAM-1 expression was upregulated in the ipsilateral striatum. However, neither IFN-β treatment nor neutrophil depletion prevented the upregulation of ICAM-1. Subsequent immunofluorescence analysis of the brains of animals used in the previously discussed stroke study (Veldhuis et al., 2002) showed that the protection afforded by IFN-β against transient ischemia was also not mediated by an effect on ICAM-1 expression (W. B. Veldhuis, unpublished observations, 2002). Thus, IFN-β prevented the influx of neutrophils without preventing the upregulation of membrane-bound ICAM-1. Increased shedding of membrane-bound adhesion molecules, thereby increasing the soluble fraction of the adhesion molecule in the blood stream, has been reported for both vascular cell adhesion molecule and ICAM after IFN-β treatment in multiple sclerosis (Calabresi et al., 2001; Kallmann et al., 2000; Trojano et al., 1999). The soluble form of adhesion molecules may inhibit the adhesion of leukocytes to endothelial cells by binding to their leukocyte counterreceptors in the bloodstream. This mechanism may have contributed to the observed reduction in neutrophil influx reported here after IL-8 injection in IFN-β–treated animals.

IFN-β reduces MMP-9 expression

Interferon-beta may impede the access of inflammatory cells to the brain parenchyma not only via an effect on adhesion molecule expression, but also via downregulation of proteolytic MMP-9 activity (Galboiz et al., 2001; Stuve et al., 1997; Trojano et al., 1999; Waubant et al., 2001). In the current study, we show that IFN-β directly prevents neutrophil-mediated BBB disruption. Using gelatinase zymography, the BBB disruption depended on both the presence of neutrophils and the expression of MMP-9. After cerebral ischemia, IL-8–induced neutrophil chemotaxis is central to the acute phase of the inflammatory response. The finding that IFN-β reduces MMP-9 in this setting is of putative therapeutic relevance, because it has been shown that knocking out or inhibiting MMP-9 reduces ischemic brain injury in the mouse (Asahi et al., 2000) and rat (Romanic et al., 1998). Moreover, MMP-9 is also directly associated with the risk of hemorrhagic transformation after stroke in general (Montaner et al., 2001) and after tissue plasminogen activator treatment in particular (Sumii and Lo, 2002). Tissue plasminogen activator is currently the only treatment available for acute ischemic stroke patients, and its application is limited by this risk of hemorrhagic transformation. MMP-9 is probably more important in this respect than MMP-2, because in the rat, MMP-2 was shown to be constitutively present in the brain and transient (1-hour) ischemia resulted in a greatly enhanced MMP-9 activity, whereas MMP-2 only very slightly increased during the first days (Planas et al., 2001). In a murine stroke model, MMP-2 activity was not increased after ischemia, and knocking out MMP-2 had no effect on brain injury after permanent or transient (2-hour) ischemia (Asahi et al., 2001).

Importantly, in neutrophil-depleted animals MMP-9 expression was also diminished, whereas no difference in MMP-2 expression was observed. This suggests that neutrophils are the predominant source of MMP-9 in this setting. This suggestion and its relevance to cerebral ischemia are directly confirmed by the results from a recent study in which bone marrow cells from MMP-9 knockout mice were transplanted into irradiated wild-type mice or wild-type cells were transplanted into MMP-9 knockouts, after which the mice were subjected to ischemia (Shah et al., 2002). Mice transplanted with MMP-9–knockout cells showed less BBB injury, smaller infarct volumes, and reduced neutrophil infiltration, whereas transplantation with wild-type cells did not afford any protection. Thus, we propose that IFN-β prevents the release of MMP-9 from neutrophils, thereby preventing their infiltration and preventing the escalation of inflammation.

It has also been shown that IFN-β directly reduces MMP-9 mRNA levels in nonimmune cells; e.g., in human astroglioma and fibrosarcoma cell lines and primary astrocytes stimulated with TNF-α (Ma et al., 2001). In addition, IL-8 may directly induce MMP-9 (Cross and Woodroofe, 1999), which may be prevented by IFN-β. However, given the absence of MMP-9 expression in neutrophil-depleted animals, these mechanisms most likely do not underlie the effects of IFN-β in the current setting.

Finally, we cannot exclude the possibility that the effect on MMP-9 was secondary to an as yet undefined effect of IFN-β on neutrophil activity or chemotaxis. Regarding the latter possibility, the only identified direct effect of IFN-β on neutrophil chemotaxis is the inhibition of IL-8 mRNA expression (Oliveira et al., 1992). Although this is of possible relevance to IFN-β treatment in a setting of ischemia, it is unlikely to explain the results in the current assay, where IL-8 was exogenously administered.

CONCLUSION

We have shown that IFN-β inhibited IL-8–induced neutrophil pleocytosis and BBB damage in the rat brain, and that this effect was presumably mediated by reducing MMP-9 release from neutrophils. The latter may be of relevance to thrombolytic therapy in acute ischemic stroke because MMP-9 is directly associated with the risk of hemorrhagic transformation, both after stroke in general (Montaner et al., 2001), and after tissue plasminogen activator treatment in particular (Sumii and Lo, 2002).

Interferon-beta may thus be used as a (co)treatment in disorders where acute inflammation contributes to brain injury, particularly brain ischemia (Matsumoto et al., 1997b; Veldhuis et al., 2002), but also for example traumatic brain injury (Kossmann et al., 1997), or lipopolysaccharide-induced meningitis (Dumont et al., 2000). Because IFN-β has already been approved for other human use, it may be tested with relative rapidity in a clinical trial for its efficacy in these disorders.

References

Andersson

Perry

Gordon

(1992) Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J Exp Med 176:255–259

Anthony

Dempster

Fearn

(1998) CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr Biol 8:923–926

Asahi

Jung

del Zoppo

Fini

(2000) Role for matrix metalloproteinase 9 after focal cerebral ischemia: Effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681–1689

Asahi

Sumii

Fini

Itohara

(2001) Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 12:3003–3007

Baggiolini

Loetscher

Moser

(1995) Interleukin-8 and the chemokine family. Int J Immunopharmacol 17:103–108

Barone

Arvin

White

(1997) Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 28:1233–1244

Barone

Feuerstein

(1999) Inflammatory mediators and stroke: New opportunities for novel therapeutics. J Cereb Blood Flow Metab 19:819–834

Bell

Taub

Perry

(1996) Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience 74:283–292

Bernardes-Silva

Anthony

Issekutz

Perry

(2001) Recruitment of neutrophils across the blood-brain barrier: The role of E- and P-selectins. J Cereb Blood Flow Metab 21:1115–1124

10.

Blamire

Anthony

Rajagopalan

Sibson

Perry

Styles

(2000) Interleukin-1beta -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: A magnetic resonance study. J Neurosci 20:8153–8159

11.

Calabresi

Prat

Biernacki

Rollins

Antel

(2001) T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells. J Neuroimmunol 115:161–167

12.

Corsini

Gelati

Dufour

(1997) Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: An in vivo and in vitro study. J Neuroimmunol 79:76–83

13.

Cross

Woodroofe

(1999) Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 28:183–189

14.

de Graaf

Braun

Nicolay

(2001) Single-shot diffusion trace (1)H NMR spectroscopy. Magn Reson Med 45:741–748

15.

Defazio

Livrea

Giorelli

(2000) Interferon beta-1a downregulates TNFalpha-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. Brain Res 881:227–230

16.

DeGraba

(1998) The role of inflammation after acute stroke: Utility of pursuing anti- adhesion molecule therapy. Neurology 51:S62–68

17.

Der

Zhou

Williams

Silverman

(1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95:15623–15628

18.

Dijkhuizen

Berkelbach van der Sprenkel

Tulleken

Nicolay

(1997) Regional assessment of tissue oxygenation and the temporal evolution of hemodynamic parameters and water diffusion during acute focal ischemia in rat brain. Brain Res 750:161–170

19.

Dumont

Car

Voitenok

(2000) Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. Infect Immun 68:5756–5763

20.

Ehrlich

Sheng

(1998) Cytokine regulation of human microglial cell IL-8 production. J Immunol 160:1944–1948

21.

Floris

Ruuls

Wierinckx

(2002) Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 127:69–79

22.

Galboiz

Shapiro

Lahat

Rawashdeh

Miller

(2001) Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 50:443–451

23.

Iadecola

Alexander

(2001) Cerebral ischemia and inflammation. Curr Opin Neurol 14:89–94

24.

Kallmann

Hummel

Lindenlaub

Ruprecht

Toyka

Rieckmann

(2000) Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 123:687–697

25.

Kossmann

Stahel

Lenzlinger

(1997) Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab 17:280–289

26.

Liu

Clark

McDonnell

(1994) Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 25:1481–1488

27.

Lou

Gasche

Zheng

(1999) Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest 79:1015–1025

28.

Qin

Benveniste

(2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: Critical role of STAT-1alpha. J Immunol 167:5150–5159

29.

Matsukawa

Yoshimura

Maeda

Ohkawara

Takagi

Yoshinaga

(1995) Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo. J Immunol 154:5418–5425

30.

Matsumoto

Ikeda

Mukaida

(1997a) Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 77:119–125

31.

Matsumoto

Yokoi

Mukaida

(1997b) Pivotal role of interleukin-8 in the acute respiratory distress syndrome and cerebral reperfusion injury. J Leukoc Biol 62:581–587

32.

Montaner

Alvarez-Sabin

Molina

(2001) Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762–2767

33.

Mori

del Zoppo

Chambers

Copeland

Arfors

(1992) Inhibition of polymorphonuclear leukocyte adherence suppresses no- reflow after focal cerebral ischemia in baboons. Stroke 23:712–718

34.

Mukaida

Harada

Matsushima

(1998a) Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 9:9–23

35.

Mukaida

Matsumoto

Yokoi

Harada

Matsushima

(1998b) Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8). Inflamm Res 47 (Suppl 3):S151–S157

36.

Neumann-Haefelin

Brinker

Uhlenkuken

Pillekamp

Hossmann

Hoehn

(2002) Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: An MRI investigation in rat brain. Stroke 33:1392–1398

37.

Oliveira

Sciavolino

Lee

Vilcek

(1992) Downregulation of interleukin 8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A 89:9049–9053

38.

Olsson

Kelic

Edlund

(1994) Neuronal interferon-gamma immunoreactive molecule: Bioactivities and purification. Eur J Immunol 24:308–314

39.

Planas

Sole

Justicia

(2001) Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8:834–846

40.

Romanic

White

Arleth

Ohlstein

Barone

(1998) Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020–1030

41.

Rosen

Belliveau

Vevea

Brady

(1990) Perfusion imaging with NMR contrast agents. Magn Reson Med 14:249–265

42.

Rosenberg

Estrada

Dencoff

Stetler-Stevenson

(1995) Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window. Brain Res 703:151–155

43.

Rothwell

Luheshi

(2000) Interleukin 1 in the brain: Biology, pathology and therapeutic target. Trends Neurosci 23:618–625

44.

Runge

Kirsch

Wells

Dunworth

Woolfolk

(1994) Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: Value of administering a high dose of contrast material. AJR Am J Roentgenol 162:431–435

45.

Ruuls

de Labie

Weber

(1996) The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J Immunol 157:5721–5731

46.

Shah

Park

Gasche

Copin

Chan

Gidday

(2002) Leukocyte-derived MMP9 mediates brain injury following transient focal stroke. Society for Neuroscience Online Abstract No. 389.1

47.

Sibson

Blamire

Perry

Styles

Anthony

(2001) MRI detection of early reductions in cerebral perfusion following focal striatal injection of the cytokine TNF-alpha: Implications for CNS disease. Proc Int Soc Mag Reson Med 9:1478

48.

Sibson

Blamire

Perry

Styles

Anthony

(2002) MRI determination of the mechanisms underlying TNF-alpha-induced changes in cerebral blood volume, tissue water diffusion and BBB permeability. Proc Int Soc Mag Reson Med 10:346

49.

Stanimirovic

Satoh

(2000) Inflammatory mediators of cerebral endothelium: A role in ischemic brain inflammation. Brain Pathol 10:113–126

50.

Stanimirovic

Zhang

Howlett

Lemieux

Smith

(2001) Inflammatory gene transcription in human astrocytes exposed to hypoxia: Roles of the nuclear factor-kappaB and autocrine stimulation. J Neuroimmunol 119:365–376

51.

Stone

Frank

Albert

(1995) The effect of interferonbeta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37:611–619

52.

Stuve

Chabot

Jung

Williams

Yong

(1997) Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 80:38–46

53.

Sumii

(2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831–836

54.

Tada

Sawamura

Sakuma

(1993) Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas. Cancer Immunol Immunother 36:251–259

55.

Trojano

Avolio

Liuzzi

(1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53:1402–1408

56.

Trojano

Defazio

Avolio

(2000) Effects of rIFN-beta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. J Neurovirol 6(Suppl 2):S47–S51

57.

Tschesche

Zolzer

Triebel

Bartsch

(2001) The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. Eur J Biochem 268:1918–1928

58.

van der Meide

de Labie

Ruuls

(1998) Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 84:14–23

59.

van Goor

Fidler

Weening

Grond

(1991) Determinants of focal and segmental glomerulosclerosis in the rat after renal ablation. Evidence for involvement of macrophages and lipids. Lab Invest 64:754–765

60.

Veldhuis

van der Meide

Bär

Nicolay

(2002) Delayed treatment with interferon-beta protects against transient ischemic stroke in the rat. Stroke 33:346

61.

Wang

Shuaib

(2002) Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 67:161–172

62.

Watts

Wright

Atkinson

Merchant

(1989) Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human recombinant interleukin 2. Neurosurgery 25:202–208

63.

Waubant

Gee

Miller

Stabler

Goodkin

(2001) Ifn-beta1a may increase serum levels of timp-1 in patients with relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 21:181–185

64.

Yamagami

Tamura

Hayashi

(1999) Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats. J Leukoc Biol 65:744–749

65.

Yamasaki

Kikuchi

Moritake

(1992) A morphological and ultrastructural investigation of normal mouse brain tissue after intracerebral injection of tumor necrosis factor. J Neurosurg 77:279–287

66.

Yamasaki

Matsuo

Matsuura

Onodera

Itoyama

Kogure

(1995) Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. Stroke 26:318–322

67.

Yan

Borregaard

Kjeldsen

Moses

(2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinaseassociated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258–37265

68.

Yong

Chabot

Stuve

Williams

(1998) Interferon beta in the treatment of multiple sclerosis: Mechanisms of action. Neurology 51:682–689

69.

Zhang

Gottschall

(1997) Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinitysupport purification. J Neurosci Methods 76:15–20

Interferon-Beta Prevents Cytokine-Induced Neutrophil Infiltration and Attenuates Blood–Brain Barrier Disruption

Abstract

Keywords

MATERIALS AND METHODS

Animal model

Recombinant rat IFN-β

Magnetic resonance imaging

Experimental protocol

Immunofluorescence microscopy

Gelatinase zymography

Data analysis

RESULTS

Effect of IL-8 injection on BBB integrity

Effect of neutrophil depletion and IFN-β treatment on IL-8–induced BBB disruption

Effects of IL-8 injection and therapeutic intervention on hemodynamic parameters

Effect of IFN-β on neutrophil infiltration and cellular activation

MMP-9 activity after IFN-β treatment

DISCUSSION

Intracerebral IL-8 injection results in neutrophil influx and BBB disruption

IFN-β prevents IL-8–induced neutrophil influx and attenuates BBB disruption

IFN-β reduces MMP-9 expression

CONCLUSION

References